Ustekinumab

Study	Exclusion reasons	Rmk	Reference
De Lorenzo, 2020	not relevant exposure	EXCLUDED: no exposure to Ustekinumab.	De Lorenzo Pharmacol. Res. 2020; 152:104583 10.1016/j.phrs.2019.104583
Beaulieu, 2018	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: Analyses performed for the group of pregnancies exposed to biologic exposed patients, without analysis for each substance : 27 were on infliximab, 7 on adalimumab, 3 on certolizumab, 2 each on natalizumab and ustekinumab, and 1 on vedolizumab.	Beaulieu DB Clin Gastroenterol Hepatol 2018;16:99-105 10.1016/j.cgh.2017.08.041
Broms, 2018	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: analysis performed according illness status without distinction between treatments.	Broms Acta Derm. Venereol. 2018; 98:728-734 10.2340/00015555-2923
Polachek, 2019	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: analysis according to maternal illness, without distinction between treatments.	Polachek Clin. Rheumatol. 2019; 38:895-902 10.1007/s10067-018-4385-7